期刊文献+

阻断胰腺癌平衡型核苷转运载体对5-氟尿嘧啶诱导细胞凋亡及细胞周期改变的影响 被引量:2

Effects on 5-Fluorouracil Induced Apoptosis and Cell Cycle Changes via Blocking Human Equilibrative Nucleoside Transporters in Pancreatic Cancer Cell Membrane
原文传递
导出
摘要 目的研究应用潘生丁(DP)阻断平衡型核苷转运载体(hENTs)后,5-氟尿嘧啶(5-FU)对胰腺癌细胞株Panc-1凋亡及细胞周期的影响。方法将Panc-1细胞分为hENTs未阻断组和hENTs阻断组,hENTs阻断组再根据DP浓度分为5μmol/L DP组和10μmol/L DP组。各组细胞分别在含有1.5×106ng/L 5-FU或不含5-FU的培养液中培养24 h后,流式细胞仪检测细胞的凋亡率和细胞周期改变。结果①各组细胞凋亡检测结果:在含有1.5×106ng/L 5-FU培养液中培养24 h后,5μmol/L及10μmol/L DP组的细胞凋亡率明显高于未阻断组(P<0.05),10μmol/L DP组又明显高于5μmol/L DP组(P<0.05);在不含5-FU的培养液中培养24 h后,各组之间细胞凋亡率比较差异无统计学意义(P>0.05)。②各组细胞周期检测结果:在含有1.5×106ng/L 5-FU培养液中培养24 h后,未阻断组细胞进入合成期(S期)的比例减少,停滞在合成前期(G1期),5μmol/L DP组及10μmol/L DP组的细胞进入合成期(S期)的比例较未阻断组进一步减少(P<0.05),且随着DP浓度的增加,细胞进入合成期(S期)的比例减少得更多(P<0.05),5μmol/L DP组和10μmol/L DP组进入合成期(S期)的比例分别是未阻断组的87.09%和74.06%。5-FU对细胞合成后期(G2期)的影响较小,除5μmol/L DP组较未阻断组G2期细胞数量增加有统计学意义(P<0.05)外,其余各组之间差异均无统计学意义(P>0.05);在不含5-FU的培养液中培养24 h后,各组细胞周期中各期无明显改变,各组之间比较差异均无统计学意义(P>0.05)。结论在胰腺癌细胞株Panc-1中,DP阻断细胞膜上hENTs后,能显著增强5-FU对胰腺癌细胞促凋亡作用及抑制胰腺癌细胞分裂增殖的作用,这种增强作用可能与阻断hENTs后细胞内5-FU浓度提高有关,而与DP本身作用无关。 Objective To investigate the effects of dipyridamole (DP), one of the human equilibrative nucleo- side transporters (hENTs) blockers, on 5-fluorouracil (5-FU) induced cell apoptosis and cell cycle changes of the pancreatic cancer Pane-1 cell line. Methods Pancreatic cancer cell line Panc-1 was divided into hENTs blocked group and hENTs unblocked group. The hENTs blocked group was further divided into two subgroups according to the DP concentration, 5μmol/L DP group and 10μmol/L DP group. Each group was incubated in culture medium with or without 1.5×106 ng/L 5-FU for 24 h. Cell apoptosis and cell cycle were detected by flow cytometry. Re- sults ①The apoptosis results of each group= Incubated in culture medium with 1.5×10~ ng/L 5-FU for 24 h, the apoptosis rates of 5μmol/L DP group and 10 μmol/L DP group were higer than those of hENTs unblocked group (P〈0.05), and which of 10μmol/L DP group was higer than that of 5μmol/L DP group (P〈0.05). Incubated in culture medium without 5-FU for 24 h, there were no significant differences of the apoptosis rates among three groups (P〉0.05). ②The cell cycle results of each group: Incubated in culture medium with 1.5×10^6 ng/L 5-FU for 24 h, the percentages of S phase cells in the 5 μmol/L DP group and 10μmol/L DP group were less than those of hENTs unblocked group (P〈0.05). The percentage of S phase cell of 5μmol/L DP group reduced to 87.09%and that of 10μmol/L DP group reduced to 74.06% as compared with hENTs unblocked group. 5-FU had little in- fluence on G2 phase (P〉0.05) except for the percentage of G2 phase cells in the 5μmol/L DP group increased sig- nificantly (P〈0.05) as compared with the hENTs unblocked group. Incubated in culture medium without 5-FU for 24 h, there were no significant differences of the cell cycles among three groups (P〉0.05). Conclusions In pancre- atic cancer Panc-1 cell, DP could enhance the cytotoxicity of 5-FU by blocking hENTs. The enhanced cytotoxicity is related to elevation of 5-FU concentration in cells, and unrelated to DP itself.
出处 《中国普外基础与临床杂志》 CAS 2011年第4期396-400,共5页 Chinese Journal of Bases and Clinics In General Surgery
关键词 细胞凋亡 细胞周期 核苷转运载体 5氟尿嘧啶 潘生丁 Cell apoptosis Cell cycle Nucleoside transporter 5-fluorouracil Dipyridamole
  • 相关文献

参考文献26

  • 1刘胜利,王晶敏,鞠煌先,朱广华,杜丹,朱春富,徐皓,黄海.潘生丁抑制平衡型核苷转运蛋白对5氟尿嘧啶在胰腺癌细胞内浓聚的影响[J].中国药科大学学报,2003,34(6):544-548. 被引量:6
  • 2高毅明,刘胜利.阻断胰腺癌细胞膜hENTs对氟尿嘧啶细胞毒性的影响[J].现代医学,2006,34(3):149-153. 被引量:5
  • 3Tanaka M, Javle M, Dong X, et al. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancre atic cancer [J]. Cancer, 2010, 116(22): 5325-5335.
  • 4Santini D, Schiavon G, Vincenzi B, et al. Human equilibra rive nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) [J]. Curr Cancer Drug Targets, 2010 Jun 25 [Epub ahead of print].
  • 5Santini D, Vincenzi B, Fratto ME, et al. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer [J]. J Cell Physiol, 2010, 223 (2): 384-388.
  • 6Mar6chal R, Mackey JR, Lai R, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine ther apy in resected pancreatic adenocarcinoma [J]. Clin Cancer Res, 2009, 15(8): 2913-2919.
  • 7Kong W, Engel K, Wang J. Mammalian nucleoside trans porters [J]. Curr Drug Metab, 2004, 5(1): 63-84.
  • 8Farrell J J, nueleoside in patients Elsaleh H, Garcia M, etal. transporter 1 levels predict res Human equilibrative gemcitabine with pancreatic cancer [J]. Gastroenterology 2009, 136(1): 187-195.
  • 9Michalski CW, Erkan M, Sauliunaite D, et al. Ex vivo chemosensitivity testing and gene expression profiling predict re sponse towards adjuvant gemcitabine treatment in pancreatic cancer[J]. Br J Cancer, 2008, 99(5): 760-767.
  • 10Santini D, Vincenzi B, Fratto ME, et al. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer [J]. J Cell Physiol, 2010, 223 (2) : 384-388.

二级参考文献10

  • 1GARCIA-MANTEIGA J,MOLINA-ARCAS M,CASADO F J,et al.Nucleoside transporter profiles in human pancreatic cancer cells:role of hCNT1 in 2',2 '-difluorodeoxycytidine-induced cytotoxicity[J].Clin Cancer Res,2003,9 (13):5000-5008.
  • 2CHANDLER N M,CANETE J J,CALLERY M P.Caspase-3drives apoptosis in pancreatic cancer cells after treatment with gemcitabine[J].J Gastrointest Surg,2004,8 (8):1072-1078.
  • 3MACKEY J R,YAO SYM,SMITH K M,et al.Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters[J].J Natl Cancer Inst,1999,91 (21):1876-1881.
  • 4KONG W,ENGEL K,WANG J.Mammalian nucleoside transporters[J].Curr Drug Metab,2004,5 (1):63-84.
  • 5ACHIWA H,OGURI T,SATO S,et al.Determinants of sensitivity and resistance to gemcitabine:the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer[J].Cancer Sci,2004,95 (9):753-757.
  • 6de TOLEDO R A,CASTILHO M,MAZO L H.Determination of dipyridamole in pharmaceutical preparations using square wave voltammetry[J].J Pharm Biomed Anal,2005,36 (5):1113-1117.
  • 7Bengt Glimelius. Chemotherapy in the treatment of cancer of the pancreas[J] 1998,Journal of Hepato - Biliary - Pancreatic Surgery(3):235~241
  • 8熊小强,朱兆华,文卓夫,王连源.晚期胰腺癌的持续腹腔动脉插管化疗[J].实用癌症杂志,1999,14(3):208-210. 被引量:2
  • 9刘胜利,Helmut Friess,Jorg Kleeff,Markus W Bchler.胰腺癌细胞株对氟尿嘧啶存在固有不敏感性[J].中国药科大学学报,2002,33(6):492-495. 被引量:3
  • 10刘胜利,王晶敏,鞠煌先,朱广华,杜丹,朱春富,徐皓,黄海.潘生丁抑制平衡型核苷转运蛋白对5氟尿嘧啶在胰腺癌细胞内浓聚的影响[J].中国药科大学学报,2003,34(6):544-548. 被引量:6

共引文献11

同被引文献21

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部